Asthma and COPD Therapies Market Forecast 2014-2024

LONDON, December 3, 2014 /PRNewswire/ --

Opportunities for Leading Companies 

Report Details  

Asthma and COPD therapies - new study showing you trends, R&D progress, and predicted revenues
Where's the asthma and COPD therapies market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 335-page report provides 264 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of six exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
• Clive Page, Professor of Pharmacology, King's College London
• Monica Fletcher, Chief Executive, Education for Health
• Daphne Tsitoura, Senior Medical Director, GSK
• Barbara Yawn, Director of Research, Olmsted Medical Center
• Ahmed Wagih, Product Manager, Respiratory Franchise, GSK

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for the following submarkets:
• Bronchodilator monotherapy - SABAs, LABAs, anticholinergic drugs
• Anti-inflammatory drugs - inhaled corticosteroids, anti-leukotrienes, monoclonal antibodies
• Combination drugs.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading drugs and promising products currently in development perform to 2024 at world level? Our study forecasts sales of 27 products, including these:
• Advair/Seretide
• Atrovent
• Combivent
• Flixotide/Flovent
• Pulmicort
• Singulair
• Spiriva
• Symbicort
• Ventolin
• Xolair
• Reslizumab
• Mepolizumab

Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
• Japan
• China
• Germany
• France
• UK
• Italy
• Spain
• India
• Brazil
• Russia
• Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, Russia, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for asthma and COPD therapies will reach $33.1bn in 2014, our work forecasts. We predict slow revenue growth from 2014 to 2018 and faster growth from 2018 to 2024. Rising demand for asthma and COPD drugs, expanding healthcare coverage, new drugs for severe asthma and a strong R&D pipeline will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 7 leading companies, including these:
• AstraZeneca
• Boehringer Ingelheim
• GSK
• Merck
• Novartis
• Roche
• Teva.

A company profile gives you the following information:
• Revenue forecast for asthma and COPD drugs from 2014 to 2024
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You see trends for these areas:
• Bronchodilators
• Anti-inflammatory drugs
• Combination drugs
• Other progress in asthma and COPD.

Our study also discusses these agents and technologies, among others:
• Monoclonal antibodies
• Muscarinic antagonists and beta-agonists (MABAs)
• Once-daily combination products
• Triple combination therapies
• Generic combination drugs
• Other novel small molecules including CRTH2 inhibitors.

Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the asthma and COPD therapies industry?
Our new report discusses issues and events affecting the asthma and COPD therapies market. You will find discussions, including qualitative analyses:
• Increasing demand for asthma and COPD drugs due to increasing prevalence
• A strong anti-inflammatory drugs R&D pipeline
• Patent expiry and generic competition
• Growth areas such as monoclonal antibodies and once-daily combination drugs
• Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary, our 335-page report gives you the following knowledge:
• Revenue forecasts to 2024 for the world asthma and COPD therapies market and 3 product categories (therapeutic classes) - discover the industry's prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 12 national markets - US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
• Assessment of 7 leading companies - hear about products, results and strategies including revenue forecasts for asthma and COPD drugs to 2024
• Predicted revenues of 27 leading drugs to 2024 - see potentials of top products
• Review of R&D pipelines - investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the asthma and COPD therapies market and leading companies. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1338/Asthma-and-COPD-Therapies-Market-Forecast-2014-2024

Companies Listed on this report 

3M Drug Delivery Systems
AB Science
Actavis
Actelion
Adamis Pharmaceuticals
Advinus Therapeutics
Alba Therapeutics
Alcon (part of Novartis)
Alembic
AlgiPharma
Allen and Hanburys (subsidiary of GSK)
Almirall
Amakem
Amgen
Ampio Pharmaceuticals
Apellis Pharmaceuticals
Apotex
Ario Pharma
Array BioPharma
Aslan Pharma
Asmacure
Aspen Pharmacare
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Axikin Pharmaceuticals
Bayer
Bellerophon
Ben Venue Laboratories (subsidiary of Boehringer Ingelheim)
Biogen Idec
Bioneer Corporation
BioTech Tools
BioWa (subsidiary of Kyowa Hakko Kirin)
BioXpress Therapeutics
Bioxyne
Boehringer Ingelheim
Breath Limited
Carolus Therapeutics
Catalent Pharma Solutions
Cempra
Cephalon (acquired by Teva)
Ception Therapeutics (acquired by Cephalon)
Chiesi Farmaceutici
Cipla
Clarassance
Concert Pharmaceuticals
Corridor Pharmaceuticals
CVS Caremark
Cytokinetics
Daewoong Pharmaceutical
Dainippon Sumitomo
Dr. Reddy's Laboratories
Dynavax Technologies
Eli Lilly and Company (Lilly)
Express Scripts
Foresee Pharmaceuticals
Forest Laboratories (part of Actavis)
Fountain Biopharma
Genentech (subsidiary of Roche)
GlycoMar
Grifols
GSK
Hydra Biosciences
iCeutica
Ikaria
Immune Pharmaceuticals
Infinity Pharmaceuticals
Invida (subsidiary of Menarini)
Invion
Johnson & Johnson
Kamada
Kyorin Pharmaceutical
Kyowa Hakko Kirin
Lallemand Pharma
Ligand Pharmaceuticals
Marinomed
Medestea Research & Production
MediciNova
MedImmune (subsidiary of AstraZeneca)
Menarini
Merck & Co. (Merck)
Merck KGaA
MicroDose Therapeutx
MSM Protein Technologies
Mylan Pharmaceuticals
N30 Pharmaceuticals
Novartis
Nycomed (subsidiary of Takeda)
Omega Pharma
Ono Pharma
OPKO Health
Orion Corporation
Otsuka Pharmaceutical
Panmira Pharmaceuticals
Pearl Therapeutics (acquired by AstraZeneca)
Peptinnovate
Perrigo
Pfizer
PharmaLundensis
Pharmaxis
Polyphor
Portola Pharmaceuticals
Prestige Brands
Promedior
Propeller Health
Prosonix
Protalix BioTherapeutics
Pulmagen
Pulmatrix
Reckitt Benckiser
Regeneron
Resolvyx Pharmaceuticals
Respiratorius
Revalesio
Rhizen Pharmaceuticals
Roche
Sandoz (division of Novartis)
Sanofi
Schering-Plough (part of Merck)
Seoul Pharma
Skyepharma
Sofotec (acquired by AstraZeneca)
Sosei Group
Spring Bank Pharmaceuticals
Stallergenes
S-TARget therapeutics
Stelic Institute & Co.
Stempeutics
sterna biologicals
Sun Pharma
Sunovion Pharmaceuticals (subsidiary of Dainippon Sumitomo)
Synairgen
Syntrix Biosystems
Takeda
Tanox
Targacept
Teva
Theravance Biopharma
Theron Pharmaceuticals
TransTech Pharma
UCB
Vectura Pharma
Verona Pharma
Watson (now Actavis)
Yuhan Corporation
Yungjin Pharmaceutical
Zambon
Zeltia

Other Organisations Mentioned in this Report
Agência Nacional de Vigilância Sanitária (ANVISA) (Brazil)
Agenzia Italiana del Farmaco (AIFA) (Italy)
American Lung Association
Asthma Institute, University of Pittsburgh
Babraham Biotechnology Ltd
Babraham Institute, Cambridge
Bank of Spain
Department of Pharmaceuticals (India)
Education for Health
European COPD Coalition
European Federation of Allergy and Airway Diseases (EFA)
European Lung Foundation (ELF)
European Medicines Agency (EMA)
European Patent Office
European Respiratory Society (ERS)
Federal Commission for the Protection against Sanitary Risk (COFEPRIS) (Mexico)
Global Initiative for Asthma (GINA)
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
King's College London
National Health Service (NHS) (UK)
National Institute for Health and Care Excellence (NICE) (UK)
National Pharmaceutical Pricing Authority (NPPA) (India)
Olmsted Medical Center
Pan American Health Organization (PAHO)
Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
Sackler Institute of Pulmonary Pharmacology
Servicio Sanitario Nazionale (SSN) (Italy)
Sistema Único de Saúde (SUS) (Brazil)
Society of Biology
South Asia Network for Chronic Disease
United States Centers for Disease Control and Prevention (CDC)
United States Food and Drug Administration (FDA)
University of Michigan Medical School
University of Minnesota
US National Heart, Lung and Blood Institute
US National Institutes of Health
World Health Organization (WHO)

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com